A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
A phase 2 trial of AK112 in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.
Overview
A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer is a phase 2 interventional study registered as NCT07114315 by Akeso, with 160 participants planned, started 2025-09-19 and due to reach its primary completion in 2027-08. Interventions recorded: AK112 and AK130.
Similar pages
not linked directly; found by shared links- TrialA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Shares Akeso, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Akeso and the tag pipeline.
- TrialGlufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialFOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.